Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Best Practice & Research. Clinical Haematology
|
October 9, 2021
Toxicities associated with adoptive cellular therapies
Doris K Hansen, Marian Dam, Rawan G Faramand
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
Rawan G Faramand, Zhuoer Xie, Michael D Jain
International Journal of Molecular Sciences
|
May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Sepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Joseph Pidala, Kelly Walton, Hany Elmariah, et al.
Blood
|
July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results
Joseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood
|
December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial
Everett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood
|
June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention
Joseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Best Practice & Research. Clinical Haematology
|
October 9, 2021
Toxicities associated with adoptive cellular therapies
Doris K Hansen, Marian Dam, Rawan G Faramand
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
Rawan G Faramand, Zhuoer Xie, Michael D Jain
International Journal of Molecular Sciences
|
May 7, 2025
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Sepideh Mokhtari, Justin M Asquith, Syeda Saba Kareem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Joseph Pidala, Kelly Walton, Hany Elmariah, et al.
Blood
|
July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results
Joseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood
|
December 12, 2025
Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial
Everett Meyer, Amandeep Salhotra, Arpita Gandhi, et al.
Blood Cancer Discovery
|
January 9, 2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
Rawan G Faramand, Sae Bom Lee, Michael D Jain, et al.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood
|
June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention
Joseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Page
of 2